e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 16, 2010
The Medicines Company
 
(Exact Name of Registrant as Specified in Charter)
         
Delaware   000-31191   04-3324394
         
(State or Other Jurisdiction
of Incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)
     
8 Sylvan Way
Parsippany, New Jersey 		  07054
     
(Address of Principal Executive Offices)   (Zip Code)
Registrant’s telephone number, including area code: (973) 290-6000
 
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 8.01. Other Events
On March 16, 2010, The Medicines Company (the “Company”) announced that the U.S. District Court for the Eastern District of Virginia issued an order in the Company’s lawsuit against the U.S. Patent and Trademark Office, the U.S. Food and Drug Administration, the U.S. Department of Health and Human Services, et al. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
     (d) Exhibits
  99.1   Press release dated March 16, 2010 entitled “The Medicines Company Announces Decision In PTO and FDA Litigation”

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  THE MEDICINES COMPANY
 		  
Date: March 16, 2010  By:   /s/ Paul M. Antinori    
    Paul M. Antinori   
    Senior Vice President and General Counsel   

 

 

         
Exhibit Index
     
Exhibit No.   Description
 
    
99.1
  Press release dated March 16, 2010 entitled “The Medicines Company Announces Decision In PTO and FDA Litigation”